Market Insight - Big pharma wakes up to the potential of epigenetics
This article was originally published in Scrip
Executive Summary
Two significant deals between big pharmaceutical companies and small epigenetic-focused biotechnology firms have been struck in recent weeks, with more expected to follow. Dr Sukaina Virji looks at the companies at the forefront of research into the field of therapeutic epigenetics, the programmes that have caught the eye of big pharma and the potential epigenetics holds for future drug discovery.